(Axios) – For years, transgender patients have received hormone therapies “off label” — a common medical practice in which doctors prescribe treatments for a use the agency hasn’t approved. A small nonprofit formed this year with the goal of obtaining FDA approval of the drugs for gender-affirming care believes the agency’s formal OK could strengthen legal protections for the treatments and boost insurance coverage. (Read More)